Literature DB >> 26234637

Irisin levels in the progression of diabetes in sedentary women.

Iffet Dağdelen Duran1, Neşe Ersöz Gülçelik2, Mustafa Ünal2, Canan Topçuoğlu3, Sevilay Sezer3, Mazhar Müslüm Tuna2, Dilek Berker2, Serdar Güler2.   

Abstract

CONTEXT: The recently discovered peptide irisin has been hypothesized to be a regulator of body metabolism. However, studies ended up with controversial results. In the present study, we aimed to investigate irisin levels in sedentary women at different stages of prediabetes. DESIGN, SETTING, AND
SUBJECTS: We performed a cross-sectional analysis of circulating levels of irisin in 263 females similar for age and body mass index (BMI) and the groups included 52 normal glucose tolerance (NGT), 60 isolated impaired fasting glucose (IFG), 36 isolated impaired glucose tolerance (IGT), 65 both IFG and IGT and 50 type 2 diabetic patients. All patients were exercising less than 150 min/week.
RESULTS: Plasma irisin levels were significantly lower in IFG+IGT (2.86 ± 0.6 μg/mL, p: 0.019) and T2DM (2.83 ± 0,5 μg/mL, p: 0.005) patients compared to NGT (3.16 ± 0.3 μg/mL) patients. After age adjustment there was a negative correlation between irisin and BMI (r: -0.141; p: 0.031), postprandial glucose (PPG) (r: -0.142; p: 0.030), low density lipoprotein-cholesterol (LDL-C) (r: -0.138; p: 0.035) and triglyceride (TG) (r: -0.214; p: 0.001) and a positive correlation between irisin and high density lipoprotein-cholesterol (HDL-C) (r:.142; p: 0.030). After adjustment for age and BMI; PPG (r: -0. 137; p: 0.037), LDL-C (r: -0. 143; p: 0.029) and TG (r: -0.203; p: 0.002) were considered to correlate with irisin levels. Subgroup analysis revealed that TG levels were correlated with irisin levels in IFG (r: -0.347; p: 0.014) and IGT (r: -0.397; p: 0.030) patients.
CONCLUSION: In our cohort of sedentary women, irisin levels were lower in patients with IFG+IGT and with diabetes than in patients with NGT. There is no correlation between irisin levels and BMI. Irisin is a myokine decreasing gradually with the progression of glucose intolerance and T2DM and is not correlated with BMI in sedentary women.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  glucose intolerance; irisin; normal glucose tolerance

Mesh:

Substances:

Year:  2015        PMID: 26234637     DOI: 10.1016/j.clinbiochem.2015.07.098

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  11 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

3.  Association between irisin and metabolic parameters in nondiabetic, nonobese adults: a meta-analysis.

Authors:  Yan Li; Zhenbin Xu
Journal:  Diabetol Metab Syndr       Date:  2022-10-21       Impact factor: 5.395

4.  Association of Circulating Irisin Levels with Adiposity and Glucose Metabolic Profiles in a Middle-Aged Chinese Population: A Cross-Sectional Study.

Authors:  Ruibin Zhang; Tingting Fu; Xin Zhao; Yao Qiu; Xiaolin Hu; Hongyan Shi; Xiao Yin
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-30       Impact factor: 3.168

5.  The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients.

Authors:  Chia Lin Chang; Shang Yu Huang; Ya Chiung Hsu; Tzu Hsuan Chin; Yung Kuei Soong
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

6.  Role of irisin in Chinese patients with hypothyroidism: an interventional study.

Authors:  Ning Yang; Heng Zhang; Xia Gao; Li Miao; Zhi Yao; Yuan Xu; Guang Wang
Journal:  J Int Med Res       Date:  2019-02-06       Impact factor: 1.671

Review 7.  Irisin and Autophagy: First Update.

Authors:  Mirko Pesce; Patrizia Ballerini; Teresa Paolucci; Iris Puca; Mohammad Hosein Farzaei; Antonia Patruno
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

8.  Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling.

Authors:  Hong Tang; Ruili Yu; Shiying Liu; Bahetiyaer Huwatibieke; Ziru Li; Weizhen Zhang
Journal:  EBioMedicine       Date:  2016-02-27       Impact factor: 8.143

9.  The ratio of skeletal muscle mass to visceral fat area is a main determinant linking circulating irisin to metabolic phenotype.

Authors:  You-Cheol Hwang; Won Seon Jeon; Cheol-Young Park; Byung-Soo Youn
Journal:  Cardiovasc Diabetol       Date:  2016-01-20       Impact factor: 9.951

10.  Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

Authors:  Anna S Huerta-Delgado; Daniel N Roffe-Vazquez; Adrian M Gonzalez-Gil; José R Villarreal-Calderón; Oscar Tamez-Rivera; Nora A Rodriguez-Gutierrez; Elena C Castillo; Christian Silva-Platas; Gerardo Garcia-Rivas; Leticia Elizondo-Montemayor
Journal:  J Diabetes Res       Date:  2020-09-04       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.